Liaoning Chengda Biotechnology Stock EBITDA
| 688739 Stock | 27.32 0.43 1.60% |
Liaoning Chengda Biotechnology fundamentals help investors to digest information that contributes to Liaoning Chengda's financial success or failures. It also enables traders to predict the movement of Liaoning Stock. The fundamental analysis module provides a way to measure Liaoning Chengda's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Liaoning Chengda stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 1.1 B | 1.1 B |
Liaoning | EBITDA |
Liaoning Chengda Biotechnology Company EBITDA Analysis
Liaoning Chengda's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Liaoning Chengda EBITDA | 506.9 M |
Most of Liaoning Chengda's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Liaoning Chengda Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Liaoning Ebitda
Ebitda |
|
According to the company disclosure, Liaoning Chengda Biotechnology reported earnings before interest,tax, depreciation and amortization of 506.9 M. This is 42.23% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The ebitda for all China stocks is 87.0% higher than that of the company.
Liaoning EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Liaoning Chengda's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Liaoning Chengda could also be used in its relative valuation, which is a method of valuing Liaoning Chengda by comparing valuation metrics of similar companies.Liaoning Chengda is currently under evaluation in ebitda category among its peers.
Liaoning Fundamentals
| Return On Equity | 0.0346 | ||||
| Return On Asset | 0.0239 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 5.86 B | ||||
| Shares Outstanding | 416.45 M | ||||
| Shares Owned By Insiders | 61.24 % | ||||
| Shares Owned By Institutions | 2.14 % | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 6.62 X | ||||
| Revenue | 1.75 B | ||||
| Gross Profit | 1.57 B | ||||
| EBITDA | 506.9 M | ||||
| Net Income | 465.92 M | ||||
| Total Debt | 4.86 M | ||||
| Book Value Per Share | 23.20 X | ||||
| Cash Flow From Operations | 677.01 M | ||||
| Earnings Per Share | 0.81 X | ||||
| Target Price | 40.0 | ||||
| Number Of Employees | 1.73 K | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 11.38 B | ||||
| Total Asset | 10.08 B | ||||
| Retained Earnings | 4.04 B | ||||
| Working Capital | 6.89 B | ||||
| Annual Yield | 0.03 % | ||||
| Net Asset | 10.08 B | ||||
| Last Dividend Paid | 0.8 |
About Liaoning Chengda Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Liaoning Chengda Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Liaoning Chengda using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Liaoning Chengda Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Liaoning Stock
Liaoning Chengda financial ratios help investors to determine whether Liaoning Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Liaoning with respect to the benefits of owning Liaoning Chengda security.